is posted on the BOTA website.
They seem to have streamlined their strategy and it's presentation. There is no further mention of BARDA and efforts to reclaim $. The (re) analysis of LANI outcomes is encouraging.
It's organised and plausible. They have a package with near term plans for RSV at Phase 1, vapendavir at Phase 2 and LANI still sitting at Phase 3.
However, they are giving themselves all of 2015 to partner ROW LANI.
Vapendavir Phase 2b and RSV Phase 1 won't have results till mid 2016, by which time their cash position will be a lot less than now. I really wish they would look at a rapid test for rhinovirus.
The only value adding step in the near term is partnering LANI. But a year is a long time and the share price doesn't have that luxury.
No comments:
Post a Comment